StrategCations creates custom teams of independent senior-level practitioners to provide hands-on counsel, planning and program implementation under the direction of Donna K. Ramer, a 30-year industry veteran.
Donna, who honed her communications and business-building skills at a number of prestigious public relations agencies,is an award-winning communications professional who specializes in driving client businesses and building positive corporate, association and product reputations. With more than three decades of experience, Donna’s communications expertise spans the continuum of industries, most notably within the healthcare, pharmaceutical, consumer product, technology and non-profit sectors.
A lecturer in public relations, Donna is often sought for expert comment on industry issues and provides pro-bono services to a number of charitable organizations and trade associations. She was named one of the PharmaVOICE 100 Most Inspiring People in Healthcare, one of PR Week’s Top 50 Healthcare Agency Executives and the 2005 recipient of the Healthcare Businesswomen’s Association (HBA) STAR award. Donna is a member of the Public Relations Society of America and NYC Women in Communications as well as numerous online social media groups. She was a contributor to Creating Foundations for American Schools and NonProfit Mergers: The Power of Successful Partnerships (McCormick, D. H., Aspen, 2001) and the Healthcare Leadership Review.
“A pioneer in healthcare public relations, Donna Ramer, President of StrategCations, is driven to improve communications among all stakeholders within and outside a company or nonprofit organization.”
PharmaVOICE 100 Most Inspiring People in Healthcare (July/August 2009, P 109 http://viewer.zmags.com/publication/b9e7faf8
“In everything she does, Donna Ramer, President of StrategCations, is a straight shooter. Her candor, can-do attitude and straightforward approach to solving most any problem are valued by clients as well as the nonprofit organizations to which she devotes tremendous resources…”
PharmaVOICE July/August 2009 P 109